Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEC88473 vs placebo vs dulaglutide in type 2 diabetes mellitus
CTR20232481Phase 2Completed
- Sponsor
- HEC Pharm
- Start
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of HEC88473 in type 2 diabetes mellitus (T2DM), metabolic dysfunction-associated steatohepatitis (MASH), obesity, sponsored by HEC Pharm. Started Aug 2023; status: completed.
02
Drugs
HEC88473
03
Conditions
type 2 diabetes mellitus (T2DM)metabolic dysfunction-associated steatohepatitis (MASH)obesity
Beyond the preview
Go deeper on CTR20232481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232481.